Cargando…
B7-H3 specific T cells with chimeric antigen receptor and decoy PD-1 receptors eradicate established solid human tumors in mouse models
The application of chimeric antigen receptor (CAR)-T cell therapy in patients with advanced solid tumors remains a significant challenge. Simultaneously targeting antigen and the solid tumor microenvironment are two major factors that greatly impact CAR-T cell therapy outcomes. In this study, we eng...
Autores principales: | Huang, Baozhu, Luo, Liqun, Wang, Jun, He, Bailin, Feng, Rui, Xian, Na, Zhang, Qiong, Chen, Lieping, Huang, Gangxiong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959446/ https://www.ncbi.nlm.nih.gov/pubmed/32002297 http://dx.doi.org/10.1080/2162402X.2019.1684127 |
Ejemplares similares
-
Ablation of T cell–associated PD-1H enhances functionality and promotes adoptive immunotherapy
por: Hu, Li, et al.
Publicado: (2022) -
Chimeric antigen receptor T-cell therapy for solid tumors
por: Newick, Kheng, et al.
Publicado: (2016) -
New Chimeric Antigen Receptor Design for Solid Tumors
por: Wang, Yuedi, et al.
Publicado: (2017) -
Supercharged chimeric antigen receptor T cells in solid tumors
por: Pant, Ayush, et al.
Publicado: (2022) -
Chimeric antigen receptor T cells applied to solid tumors
por: Zhou, Zhongguo, et al.
Publicado: (2022)